622 related articles for article (PubMed ID: 17709460)
61. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study--a randomized clinical trial.
Torres A; Garau J; Arvis P; Carlet J; Choudhri S; Kureishi A; Le Berre MA; Lode H; Winter J; Read RC;
Clin Infect Dis; 2008 May; 46(10):1499-509. PubMed ID: 18419482
[TBL] [Abstract][Full Text] [Related]
62. Moxifloxacin monotherapy versus combination therapy in patients with severe community-acquired pneumonia evoked ARDS.
Rahmel T; Asmussen S; Karlik J; Steinmann J; Adamzik M; Peters J
BMC Anesthesiol; 2017 Jun; 17(1):78. PubMed ID: 28615012
[TBL] [Abstract][Full Text] [Related]
63. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
Segreti J; House HR; Siegel RE
Am J Med; 2005 Jul; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
[TBL] [Abstract][Full Text] [Related]
64. Monotherapy versus Combination Therapy in Patients Hospitalized with Community-Acquired Pneumonia.
Kolditz M; Halank M; Höffken G
Treat Respir Med; 2006; 5(6):371-83. PubMed ID: 17154666
[TBL] [Abstract][Full Text] [Related]
65. Coverage of atypical pathogens for hospitalised patients with community-acquired pneumonia is not guided by clinical parameters.
Piso RJ; Arnold C; Bassetti S
Swiss Med Wkly; 2013; 143():w13870. PubMed ID: 24089030
[TBL] [Abstract][Full Text] [Related]
66. How good is the evidence for the recommended empirical antimicrobial treatment of patients hospitalized because of community-acquired pneumonia? A systematic review.
Oosterheert JJ; Bonten MJ; Hak E; Schneider MM; Hoepelman IM
J Antimicrob Chemother; 2003 Oct; 52(4):555-63. PubMed ID: 12972448
[TBL] [Abstract][Full Text] [Related]
67. Survival benefit associated with clarithromycin in severe community-acquired pneumonia: A matched comparator study.
Kyriazopoulou E; Sinapidis D; Halvatzis S; Velissaris D; Alexiou N; Kosmas V; Adami ME; Kyprianou M; Kyprianou A; Stefos A; Lada M; Koutoukas P; Pavlaki M; Kyriakoudi A; Makina A; Gogos C; Niederman MS; Giamarellos-Bourboulis EJ
Int J Antimicrob Agents; 2020 Jan; 55(1):105836. PubMed ID: 31704213
[TBL] [Abstract][Full Text] [Related]
68. Current guidelines for the treatment of severe pneumonia and sepsis.
Bodmann KF
Chemotherapy; 2005 Aug; 51(5):227-33. PubMed ID: 16103664
[TBL] [Abstract][Full Text] [Related]
69. Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the Infauci study.
Pereira JM; Gonçalves-Pereira J; Ribeiro O; Baptista JP; Froes F; Paiva JA
J Crit Care; 2018 Feb; 43():183-189. PubMed ID: 28915392
[TBL] [Abstract][Full Text] [Related]
70. The science of selecting antimicrobials for community-acquired pneumonia (CAP).
File TM
J Manag Care Pharm; 2009 Mar; 15(2 Suppl):S5-11. PubMed ID: 19236135
[TBL] [Abstract][Full Text] [Related]
71. The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila.
Nakamura S; Yanagihara K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Senjyu H; Saito A; Kohno S
J Infect; 2009 Sep; 59(3):222-4. PubMed ID: 19592113
[No Abstract] [Full Text] [Related]
72. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis.
Eljaaly K; Alshehri S; Aljabri A; Abraham I; Al Mohajer M; Kalil AC; Nix DE
BMC Infect Dis; 2017 Jun; 17(1):385. PubMed ID: 28576117
[TBL] [Abstract][Full Text] [Related]
73. β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis.
Vardakas KZ; Tansarli GS; Bliziotis IA; Falagas ME
Int J Antimicrob Agents; 2013 Apr; 41(4):301-10. PubMed ID: 23410791
[TBL] [Abstract][Full Text] [Related]
74. Antibiotic treatment patterns, costs, and resource utilization among patients with community acquired pneumonia: a US cohort study.
Llop CJ; Tuttle E; Tillotson GS; LaPlante K; File TM
Hosp Pract (1995); 2017 Feb; 45(1):1-8. PubMed ID: 28064542
[TBL] [Abstract][Full Text] [Related]
75. Usefulness of β-lactam and macrolide combination therapy for treating community-acquired pneumonia patients hospitalized in the intensive care unit: Propensity score analysis of a prospective cohort study.
Ito A; Ishida T; Tachibana H; Nakanishi Y; Tokioka F; Yamazaki A; Washio Y; Irie H; Otake T
J Infect Chemother; 2021 Oct; 27(10):1447-1453. PubMed ID: 34147355
[TBL] [Abstract][Full Text] [Related]
76. Monotherapy or combination therapy for hospitalized patients with community-acquired pneumonia: not yet the end of the story?
Laterre PF
Clin Infect Dis; 2008 May; 46(10):1510-2. PubMed ID: 18419483
[No Abstract] [Full Text] [Related]
77. Efficacy and significance of various scores for pneumonia severity in the management of patients with community-acquired pneumonia in China.
Yang Y; Xu F; Shi LY; Diao R; Cheng YS; Chen XY; Jing JY; Wang XD; Shen HH
Chin Med J (Engl); 2012 Feb; 125(4):639-45. PubMed ID: 22490488
[TBL] [Abstract][Full Text] [Related]
78. [Medical outcomes and antimicrobial compliance according to the Chilean Society of Respiratory Diseases guidelines for hospitalized patients with community acquired pneumonia].
Díaz A; Kuzmanic G; Platzer L; Sanfuentes F; Espinoza MA; Saldías F
Rev Med Chil; 2003 Aug; 131(8):847-56. PubMed ID: 14558238
[TBL] [Abstract][Full Text] [Related]
79. Comparing gatifloxacin and clarithromycin in pneumonia symptom resolution and process of care.
Dean NC; Sperry P; Wikler M; Suchyta MS; Hadlock C
Antimicrob Agents Chemother; 2006 Apr; 50(4):1164-9. PubMed ID: 16569825
[TBL] [Abstract][Full Text] [Related]
80. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia.
Arnold FW; Lopardo G; Wiemken TL; Kelley R; Peyrani P; Mattingly WA; Feldman C; Gnoni M; Maurici R; Ramirez JA;
Respir Med; 2018 Jul; 140():115-121. PubMed ID: 29957272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
